Lavipharm Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 9, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	240	164	134	134	64	30
Market Cap Growth	63.41%	22.01%	0.36%	107.29%	117.58%	23.40%
Enterprise Value	267	191	157	161	98	66
Last Close Price	1.42	0.97	0.78	0.78	0.37	1.58
PE Ratio	39.99	27.32	14.93	71.42	77.29	17.20
PS Ratio	3.83	2.62	2.53	2.79	1.65	0.75
PB Ratio	-	-	2.53	3.12	1.60	-2.98
P/TBV Ratio	-	-	17.21	78.88	-	-
P/FCF Ratio	-	-	-	-	-	13.52
P/OCF Ratio	-	-	28.90	470.51	19.27	7.21
EV/Sales Ratio	4.27	3.06	2.96	3.36	2.50	1.67
EV/EBITDA Ratio	20.27	14.51	17.28	19.44	19.70	12.35
EV/EBIT Ratio	28.58	20.46	29.91	34.11	24.01	14.66
EV/FCF Ratio	-	-	-	-	-	30.17
Debt / Equity Ratio	-	-	0.64	0.76	0.92	-3.76
Debt / EBITDA Ratio	-	-	3.45	3.64	6.68	6.28
Debt / FCF Ratio	-	-	-	-	-	17.03
Net Debt / Equity Ratio	-	-	0.54	0.56	0.47	-3.59
Net Debt / EBITDA Ratio	-	-	3.12	2.91	3.82	6.66
Net Debt / FCF Ratio	-	-	-5.66	-6.39	-0.59	16.28
Asset Turnover	-	-	0.44	0.42	0.47	0.77
Inventory Turnover	-	-	1.52	1.93	2.18	2.70
Quick Ratio	-	-	0.56	0.66	0.70	0.35
Current Ratio	-	-	1.15	1.27	1.00	0.63
Return on Equity (ROE)	-	-	18.10%	4.74%	6.25%	-
Return on Assets (ROA)	-	-	2.73%	2.57%	3.04%	5.46%
Return on Invested Capital (ROIC)	15.03%	15.48%	7.08%	4.58%	4.02%	11.00%
Return on Capital Employed (ROCE)	-	-	6.10%	6.00%	5.90%	38.60%
Earnings Yield	2.50%	3.66%	6.70%	1.40%	1.29%	5.82%
FCF Yield	-	-	-3.73%	-2.82%	-50.06%	7.40%
Dividend Yield	1.41%	-	2.58%	-	-	-
Buyback Yield / Dilution	-	-	-0.17%	-681.40%	-26.42%	-
Total Shareholder Return	1.41%	-	2.40%	-681.40%	-26.42%	-

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.